Keytruda (pembrolizumab) • Yervoy (ipilimumab) • carboplatin • temozolomide • albumin-bound paclitaxel • cyclophosphamide • dacarbazine • Amtagvi (lifileucel) • relatlimab (BMS-986016) • anzutresgene autoleucel (IMA203)

Aerosolized Aldesleukin in Treating Patients With Lung Metastases (clinicaltrials.gov)

P1, N=70, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Apr 2026 --> Apr 2029 | Trial primary completion date: Apr 2026 --> Apr 2029

1 day ago

Trial completion date • Trial primary completion date

Proleukin (aldesleukin)

Single-cell sequencing reveals the functional heterogeneity of melanoma cells and their crosstalk with the tumor microenvironment. (PubMed, Front Genet)

Furthermore, High EIF5A expression was significantly associated with poor patient outcomes (p < 0.001), Immunofluorescence analysis showing significantly elevated EIF5A expression in melanoma tissues compared to controls (p < 0.01). This study reveals the functional heterogeneity of melanoma cells and their interactions with the immune microenvironment, identifies key subpopulations, prognostic signatures, and EIF5A as a plausible prognostic biomarker candidate and potential therapeutic target that warrants mechanistic validation in melanoma.

5 days ago

Journal

CD8 (cluster of differentiation 8) • CD74 (CD74 Molecule) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • CCN1 (Cellular Communication Network Factor 1) • JUN (Jun proto-oncogene)

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma (clinicaltrials.gov)

P3, N=96, Recruiting, Immatics US, Inc.

7 days ago

New P3 trial

BRAF (B-raf proto-oncogene)

BRAF mutation

ctDNA for Risk Stratification in Melanoma (clinicaltrials.gov)

P=N/A, N=296, Active, not recruiting, Herlev and Gentofte Hospital

7 days ago

New trial • Tumor mutational burden • Circulating tumor DNA

Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanoma (clinicaltrials.gov)

P2, N=35, Not yet recruiting, University of California, Irvine

8 days ago

New P2 trial

Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)

UK-EnBiRiM: UK ENcorafenib and BInimetinib Real-world Study in Melanoma (clinicaltrials.gov)

P=N/A, N=50, Active, not recruiting, Pierre Fabre Ltd | Recruiting --> Active, not recruiting

9 days ago

Enrollment closed • Real-world evidence

BRAF (B-raf proto-oncogene)

BRAF mutation • BRAF V600

Mektovi (binimetinib) • Braftovi (encorafenib)

12d

Utilising Machine Learning and Single-Cell Analysis to Uncover SKCM Metastasis-Related Genes. (PubMed, IET Syst Biol)

Through an innovative analytical strategy integrating single-cell and transcriptomic data, this study elucidated the core molecular mechanisms of SKCM metastasis and key regulatory pathways in the tumour microenvironment, providing potential biomarkers and therapeutic targets for the early diagnosis and targeted treatment of SKCM metastasis. This PSO-SVM-integrated analysis method also offers new insights for research on metastasis mechanisms of other cancers.

12 days ago

Journal

S100A8 (S100 Calcium Binding Protein A8) • TINCR (TINCR Ubiquitin Domain Containing)

13d

Phase 1 Study of PF-08046033 in Advanced Solid Tumors (clinicaltrials.gov)

P1, N=250, Not yet recruiting, Pfizer

13 days ago

New P1 trial • IO biomarker

PD-L1 (Programmed death ligand 1)

14d

Immunohistochemical and molecular profiling of uveal melanoma: clinicopathological correlations from an Italian cohort. (PubMed, Pathologica)

This study highlights the heterogeneous molecular landscape of UM and underscores the importance of integrating histopathological and molecular data for improved prognostic stratification. The identification of potential therapeutic targets and atypical mutations typically associated with other melanoma subtypes suggests avenues for future research and tailored therapeutic strategies.

14 days ago

Retrospective data • Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker

PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • PTEN (Phosphatase and tensin homolog) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • NOTCH1 (Notch 1) • GNAQ (G Protein Subunit Alpha Q) • KDR (Kinase insert domain receptor) • BAP1 (BRCA1 Associated Protein 1) • GNA11 (G Protein Subunit Alpha 11) • JAK3 (Janus Kinase 3) • H3-3A (H3.3 Histone A)

PD-L1 expression • TP53 mutation • TMB-H • BRAF mutation • PTEN mutation

14d

A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11) (clinicaltrials.gov)

P2, N=147, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Nov 2026 --> Feb 2027

14 days ago

Trial completion date

EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

PD-L1 IHC 22C3 pharmDx

Keytruda (pembrolizumab)

14d

NCI-2018-01152: MoleMapper, Visiomed, and Confocal Microscopy in Screening Participants for Melanoma (clinicaltrials.gov)

P=N/A, N=17, Terminated, OHSU Knight Cancer Institute | N=100 --> 17 | Trial completion date: Dec 2026 --> Dec 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2026 --> Dec 2025; The study did not meet its accrual goals due to the departure of study personnel. Study team opted for a study closure due to loss of key personnel.

14 days ago

Enrollment change • Trial completion date • Trial termination • Trial primary completion date